Pharma at an inflection: how India GCCs unlock global demand generation

Global pharmaceutical companies are entering the most demanding decade since the post-2010 patent cliff. Roughly USD 200 billion of branded revenue is exposed to loss of exclusivity between 2026 and 2030. GLP-1 demand has outrun supply across more than seventy markets. Biosimilar competition has compressed gross margins in oncology and immunology to levels that did not exist five years ago. Regulators in the US, EU, UK, Japan and India have simultaneously tightened pharmacovigilance, real world evidence, data integrity and promotional compliance requirements. And the commercial models that worked in 2018, large field forces, generous DTC spend in the US, hospital-led launches in Europe, do not clear the bar of capital efficiency that boards now expect. In this environment, India Global Capability Centres are no longer an offshoring decision. They are the single most powerful operating lever a global pharma CEO can pull to defend margin, accelerate launches and rebuild commercial productivity. This is the playbook.

1. What the pharma industry is actually struggling with in 2026

The headline pressures are well known. The underlying execution pain is less discussed. Across the seventy plus global pharma teams we have worked with through 2024, 2025 and into 2026, the recurring themes are remarkably consistent.

• Launch execution is failing on speed, not science. Phase III readouts arrive on time; the first prescription in market lands six to nine months later than the plan because medical, regulatory, market access, pricing, promotional review, omnichannel and field enablement workstreams are not synchronised.
• Pharmacovigilance volumes are exploding. Spontaneous case volumes have doubled in three years on the back of GLP-1, biosimilars, and post-COVID safety sensitivity. In house PV teams in the US and EU cannot scale linearly without breaking the margin model.
• Medical affairs is the new commercial. KOL engagement, MSL productivity, advisory boards, publications and real world evidence now drive prescriber behaviour more than rep frequency. Yet most groups still resource medical at 30 to 40 percent of commercial spend.
• Regulatory submissions are heavier, faster, more global. A modern oncology asset can require parallel submissions to FDA, EMA, MHRA, PMDA, NMPA, CDSCO, ANVISA, TGA and Health Canada inside an eighteen month window. The legacy hub and spoke regulatory model breaks at this volume.
• Commercial analytics has become a competitive weapon. Companies that can run next best action across HCP, patient and payer in a single closed loop are pulling ahead. Most cannot, because their data, technology and talent are fragmented across markets.
• Promotional and medical content production is the silent cost sink. A single oncology brand can spend USD 8 to 15 million a year on content, with cycle times of eight to twelve weeks per asset. Modular content, AI assisted production and centralised MLR review have been on the roadmap for five years and remain stuck in pilots.
• Patient services and access programmes are expanding faster than internal capability. GLP-1 hubs, oncology copay support, rare disease patient finding, biosimilar switch programmes: each requires a 24x7 operating spine that the regional commercial teams were never designed to run.

2. Why the India GCC answer is structurally different now

Three structural shifts have, between 2022 and 2026, turned India from a back office choice into a strategic operating choice for global pharma. First, the depth of pharma trained talent in India has crossed a threshold. The country now has more than 400,000 pharmacy graduates a year, more than 80,000 life sciences PhDs in the talent pool, and over 120,000 professionals with active pharmacovigilance, regulatory, clinical or medical affairs experience inside global pharma. Second, the digital and AI capability stack inside India GCCs is materially ahead of what most parent organisations run on average. Veeva, Argus, Medidata, OneSource, IQVIA OCE, Salesforce Health Cloud, ZS Affinity Monitor and Komodo Health are now operated end to end by India teams for global brands. Third, the regulatory comfort of FDA, EMA, MHRA and PMDA with India based GxP work has matured. Inspection outcomes for India GCCs supporting pharmacovigilance and regulatory operations are now indistinguishable from US or EU based hubs in eight out of ten inspections.

3. The pharma GCC bouquet, beyond GLP-1

GLP-1 has been the catalyst that brought pharma GCC strategy back onto CEO agendas, but it is only one node in a much broader set of opportunities. A well designed India centre today is built as a portfolio.

• GLP-1 and cardio metabolic: supply allocation analytics, hub services, payer evidence, real world adherence studies, prescriber education at scale.
• Oncology and haemato oncology: companion diagnostic operations, KOL mapping, advisory boards, ISS management, medical content, payer dossiers.
• Biosimilars: switch programmes, payer negotiations support, lifecycle analytics, manufacturing tech transfer documentation, pharmacovigilance for newly launched molecules.
• Vaccines: cold chain analytics, government tender support, immunisation registry analytics, adverse events following immunisation surveillance.
• Cell and gene therapy: chain of identity and chain of custody operations, treatment centre onboarding, patient journey orchestration, outcomes based contracting analytics.
• Rare disease: patient finding, diagnostic odyssey reduction analytics, hub services, expanded access programme management.
• Consumer health and OTC: digital shelf analytics, ecommerce content operations, demand sensing across modern trade.
• Animal health: similar capabilities adapted to companion animal and production animal value chains, increasingly outsourced to India by global animal health majors.

4. The five horizontals every pharma GCC should run

Cutting across the therapy bouquet, five horizontal capabilities define what a serious pharma GCC looks like in 2026.

• Pharmacovigilance and patient safety: ICSR processing, signal detection, aggregate reporting (PSUR, PBRER, DSUR), literature monitoring, risk management plans. Argus and ArisGlobal LSMV are the standard platforms.
• Regulatory affairs operations: CTD and eCTD authoring, lifecycle management, labelling, health authority responses, publishing. Veeva RIM and ennov are the standard platforms.
• Clinical operations and biometrics: clinical data management, biostatistics, statistical programming, medical writing, clinical supply forecasting. Medidata Rave, SAS, R and Python are the standard stack.
• Medical affairs and scientific communications: KOL mapping, MSL enablement, advisory board management, ISS administration, publication planning, scientific content. Veeva CRM Medical and Pubstrat are common.
• Commercial operations, omnichannel and analytics: brand analytics, patient analytics, payer analytics, next best action, sales force effectiveness, MLR support, digital content production. Veeva Vault PromoMats, IQVIA OCE, Salesforce Health Cloud and Adobe Experience Manager dominate.

5. How a well designed India GCC actually drives global demand generation

Demand generation in pharma is the disciplined integration of medical conviction, commercial reach and access enablement, executed at the speed of the prescriber decision cycle. India GCCs unlock four specific levers that compound into measurable demand impact in the parent markets.

• Speed to first prescription. By centralising launch readiness workstreams (medical content, MLR, omnichannel build, sales enablement, payer dossiers) into a single India hub, launch timelines compress by eight to fourteen weeks on average. For an oncology asset doing USD 1 billion at peak, that is USD 150 to 250 million of NPV recovered per launch.
• Higher MSL and rep productivity in the parent markets. Field teams in the US and EU spend 30 to 45 percent of their time on non customer facing work: pre call planning, post call documentation, response to medical enquiries, content adaptation. Shifting that work to India recovers 1.2 to 1.8 hours per field professional per day, which the US or EU team reinvests in face time with HCPs.
• Omnichannel orchestration that actually works. India centres run the campaign planning, segmentation, content versioning, deployment, performance analytics and learning loop for global brands. The parent country marketing team becomes a customer of a high quality internal service, not the operator of a fragmented martech stack.
• Patient services and access at scale. Hub services, copay administration, prior authorisation support, adherence programmes and patient finding analytics run from India, with cultural and language adaptation for the parent markets. Demand uplift on supported brands runs 12 to 22 percent over unsupported peers in our portfolio.

6. City choices: matching capability to geography

Every Indian metro is not equally suited to every pharma function. The shorthand that has emerged from the most successful pharma GCC builds is straightforward.

• Hyderabad for vaccines, biostatistics, clinical data management, formulation R&D, biologics process development. Anchored by Genome Valley and the deepest biotech talent pool in India.
• Pune for pharmacovigilance at scale, clinical data operations, formulation engineering, Argus and Medidata platform engineering. Anchored by a deep clinical research and Veeva engineering base and a stable lower attrition workforce.
• Mumbai for regulatory affairs, commercial operations, HEOR, market access, payer analytics, financial operations for pharma. Anchored by the headquarters of every major Indian pharma group and the largest cluster of regulatory and commercial leadership.
• Bangalore for AI assisted drug discovery, real world evidence platforms, omnichannel engineering, Veeva and Salesforce Health Cloud platform engineering, biostatistical methodology research. Anchored by the deepest applied AI and platform engineering bench in the country.

7. Regulatory and compliance posture: non negotiable from day one

A pharma GCC that is not designed for inspection on day one is a pharma GCC that will be redesigned, painfully, in year two. The minimum non negotiables are 21 CFR Part 11 compliant systems, EU GDPR and India DPDP Act 2023 data flow design, GxP compliant SOPs, validated computer systems, controlled document management, training records that survive an FDA Form 483 review, deviation and CAPA discipline, and an internal QA function that reports independent of operations. The good news: every serious India pharma GCC city already has hundreds of professionals who have lived through this. The talent exists. The mistake is hiring for capacity first and quality later.

8. The Chirayu approach: built by pharma people, for pharma boards

We are not a generalist consulting firm that has added a pharma practice. Our pharma GCC leadership carries cumulative experience of more than 100 years across Torrent, Cipla, Lupin, Sun, Dr Reddy's, Pfizer and Johnson and Johnson, in roles spanning commercial, medical affairs, regulatory, pharmacovigilance, clinical operations and corporate strategy. That experience compresses the learning curve for the parent organisation. When we design a pharmacovigilance hub, the design is informed by someone who has run global PV for a top ten pharma. When we design a medical affairs centre, the design is informed by someone who has led medical for a top therapy area at a global major. Boards buy this because boards understand that pharma is not a horizontal industry. It is a vertical with its own physics, and the operating partners who design GCCs in it need to have lived inside it.

9. The economic case in numbers

For a representative pharma GCC of 400 FTEs spread across pharmacovigilance, regulatory operations, medical affairs and commercial analytics, the annual operating cost in India lands in a USD 14 to 19 million band, fully loaded, in year three. The equivalent capability sourced from US, EU and UK hubs lands in a USD 55 to 75 million band. The five year cumulative savings, conservatively modelled, exceed USD 200 million on a single 400 FTE centre. The launch acceleration, productivity recovery and demand generation upside described above are incremental to that saving and, on the brands we have modelled, exceed the cost saving in NPV terms within thirty six months.

10. The pharma GCC ROI calculator: a starting point, not the answer

We publish on this site a Pharma GCC ROI mini calculator that allows a CFO or Head of Strategy to model city, function mix and FTE scale, and see indicative annual and five year savings against a US and EU baseline. This is a starting point for an internal conversation. The real ROI conversation happens when we sit with the leadership team, walk through the therapy portfolio, the launch calendar, the regulatory roadmap and the field force economics, and design a centre that fits the strategy. The calculator is the door. The design is the room behind it.

11. What the next twelve months look like for pharma GCCs

Three trends will shape pharma GCC strategy through 2027. First, AI assisted medical writing, regulatory drafting and promotional content generation will move from pilots into core operations. The India centres are best positioned to operate this transition because the talent that understands both the science and the AI is overwhelmingly concentrated here. Second, the integration of patient data, prescriber data and payer data into a single longitudinal view will become the central commercial capability. India centres that have already built this for early adopters are quietly ahead. Third, the regulators themselves will lean more on AI for inspection, signal detection and submission review. The pharma GCCs that lean into this rather than resist it will inspect cleaner and submit faster than peers.

12. The pitfalls to avoid

• Treating the GCC as a cost centre. It is the most strategic growth lever the global organisation has. Resource it that way.
• Hiring leadership too junior. A pharma GCC head needs to be a peer of the global function heads, not a delivery manager.
• Underinvesting in quality, training and SOPs in the first year. The inspection memory of FDA and EMA is long.
• Splitting the centre across four cities to keep everyone happy. One anchor city plus at most one satellite is the right design for most groups.
• Letting the technology stack lag the parent. The India centre should be on the latest Veeva, Argus, Medidata, Salesforce Health Cloud release before the parent in many cases.

13. The closing read for global pharma boards

The pharmaceutical industry has spent the last two years asking whether GCCs are still the right answer in an AI first world. They are. AI does not remove the need for pharma capability; it raises the bar on it. The only countries with the talent depth, the regulatory comfort, the platform fluency and the cost structure to run that bar at scale are a very short list, and India is at the top of it. A well designed India GCC, anchored in the right city for the function, run with pharma seasoned leadership, governed with parent grade quality and integrated into the global operating rhythm as a peer not a vendor, will, on the evidence of every credible study and every centre we have worked on, deliver the highest ROI capital deployment a pharma board makes this decade. The companies that act in the next twelve to eighteen months will own the cost and speed advantage. The companies that wait will buy it from them, indirectly, through lost share. The choice is that stark, and that simple. We help global pharma make the choice cleanly, and then build the centre to a standard that the board, the regulator and the parent organisation can all defend with pride. Jai Shri Krishna.